BridgeBio Pharma Inc. Publishes Data on Acoramidis’ Effect on Cardiovascular Mortality and Hospitalization in ATTR-CM
BridgeBio Pharma Inc. has published data on the effects of acoramidis (AG10) on cardiovascular mortality and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The document includes results from a randomized controlled trial and open-label extension, focusing on recurrent cardiovascular events and related outcomes. The full document is accessible via a provided link. This news brief was generated by Public Technologies (PUBT) and is for informational purposes only, not to be considered as financial, investment, or legal advice.
BridgeBio Pharma Inc. has published a document detailing the effects of acoramidis (AG10) on cardiovascular mortality and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The document includes results from a randomized controlled trial and open-label extension, focusing on recurrent cardiovascular events and related outcomes. The full document can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on September 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
